Replaces Prod. #: ALX-430-026
Binds reversibly to calmodulin, inhibiting calmodulin-mediated enzyme activation. It inhibits the Ca2+/calmodulin-induced activation of myosin light chain kinase in a concentration dependent manner (IC50=1 µM). Cell permeable. Inhibits calmodulin N-methyltransferase (Ki=65 nM). Blocks Ca2+-calmodulin binding to NOS. Inhibitor of voltage-gated Ca2+ channels
Product Details
| Alternative Name: | R24571 |
| |
| Formula: | C31H23Cl7N2O |
| |
| MW: | 687.7 |
| |
| CAS: | 57265-65-3 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White powder. |
| |
| Solubility: | Soluble in 100% ethanol (>100mg/ml), DMSO (>100mg/ml), methanol, chloroform or propylene glycol. Almost insoluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Neural tube closure depends on nitric oxide synthase activity: A. Nachmany et al.; J. Neurochem.
96, 247 (2006),
Abstract;
Mitochondrial calcium uptake stimulates nitric oxide production in mitochondria of bovine vascular endothelial cells: E.N. Dedkova et al.; Am. J. Physiol. Cell Physiol.
286, C406 (2004),
Abstract;
Mitochondrial nitric oxide synthase is constitutively active and is functionally upregulated in hypoxia: Z. Lacza et al.; Free. Radic. Biol. Med.
31, 1609 (2001),
Abstract;
Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells. The role of calcineurin: A. Schaefer et al.; J. Biol. Chem.
271, 13484 (1996),
Abstract;
Calmodulin N-methyltransferase. Kinetics, mechanism, and inhibitors: L.S. Wright et al.; J. Biol. Chem.
271, 12737 (1996),
Abstract;
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide-dependent activation of membrane-bound NO synthase in smooth muscle mediated by pertussis toxin-sensitive Gi1-2: K.S. Murthy & G.M. Makhlouf; J. Biol. Chem.
269, 15977 (1994),
Abstract;
The calmodulin antagonist calmidazolium stimulates release of nitric oxide in neuroblastoma N1E-115 cells: J. Hu & E.E. el-Fakahany; Neuroreport
4, 198 (1993),
Abstract;
Calmidazolium, a calmodulin inhibitor, inhibits endothelium-dependent relaxations resistant to nitro-L-arginine in the canine coronary artery: S. Illiano et al.; Br. J. Pharmacol.
107, 387 (1992),
Abstract;
Inhibitors of calmodulin impair the constitutive but not the inducible nitric oxide synthase activity in the rat aorta: V.B. Schini & P.M. Vanhoutette; J. Pharmacol. Exp. Ther.
261, 553 (1992),
Abstract;
Divergent pharmacological effects of three calmodulin antagonists, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), chlorpromazine and calmidazolium, on isometric tension development and myosin light chain phosphorylation in in: M. Asano et al.; J. Pharmacol. Exp. Ther.
251, 764 (1989),
Abstract;
A model for the regulation of the calmodulin-dependent enzymes erythrocyte Ca2+-transport ATPase and brain phosphodiesterase by activators and inhibitors: K. Gietzen et al.; Biochem. J.
207, 541 (1982),
Abstract;
